Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← KRAS / RAS targeting: from platform to Phase 3

daraxonrasib

Clinical trial

64 people · 66 posts · 6 abstracts

Heat trend for this story

Heat now 1·Peak in the comparable set 1 (Oct 23 10:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1
00.250.50.751
Heat over time
00.250.50.751Oct23Oct23Oct23Oct23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

Records
Drug / trialReadoutSetting
daraxonrasibdaraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40RASolute 302 · 2L mPDAC · Phase 3
daraxonrasib ± GnPdaraxonrasib#PANCREATICCANCER#PDACmono ORR 47%; +GnP ORR 55%, DCR 90%1L mPDAC · Phase 1

The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.

Other cases in this chapter
  • zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
  • VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
  • elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
  • RM-055Active in daraxonrasib-resistant and RAS-amplification models
Evidence
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →
Floor
Apr 20Mon
Apr 19Sun
Apr 18Sat
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org